Yiling Pharmaceutical Ciprofloxacin Hydrochloride Tablets Passed the Consistency Evaluation

Eling Pharmaceuticals is the first enterprise in the country to pass the consistent evaluation of the varietyciprofloxacin tablets are anti-infective drugs used to treat or prevent confirmed or highly suspected sensitive bacterial infections and belong to the National Health Insurance Catalog (2019 edition) and the Essential Medicines Catalog (2018 edition)ciprofloxacin tablets were first developed by Bayer (Bayer) and were listed in Germany on January 30, 1987, and the product, named Ciprobay, was announced by the State Food and Drug Administration as a reference for consistency evaluationthe company selected Bayer's production and marketed ciprofloxacin tablets in Germany as reference agents to conduct a product consistency evaluation studyThrough the detailed study of the quality attribute of the reference formulation, the method of risk assessment is used to study the key prescription factors and process parameters that affect the quality of products, and to ensure the stable and controllable quality of the products, and to confirm the bioequivalent of the hydrochloric acid cyclopase tablets of The Ling Pharmaceuticals and the original drugIn summary, the hydrochloric acid cyclopia tablets developed by Eling Pharmaceuticals reached quality and efficacy consistent with the original druga total of 108 hydrochloric acid ciprofloxacin tablets production approval, as of the date of this announcement, only Ealing Pharmaceutical research and development of citeaupropya star flakes through the National Drug Administration consistency evaluation approval.